A hypoxic ticket to the bone metastatic niche

Breast Cancer Research

Volumn 17, Issue 1, 2015, Pages

  Vanharanta, Sakari ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN LYSINE 6 OXIDASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR NFAT;

ARTICLE; BONE MATRIX; BONE METASTASIS; BONE METASTATIC NICHE; BREAST CANCER; CANCER CELL; FRACTURE; HUMAN; HYPOXIA; MORTALITY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; TUMOR MICROENVIRONMENT; BONE; BONE TUMOR; BREAST TUMOR; CELL HYPOXIA; FEMALE; METASTASIS; PATHOLOGY; PHYSIOLOGY;

BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; CELL HYPOXIA; FEMALE; HUMANS; NEOPLASM METASTASIS; TUMOR MICROENVIRONMENT;

EID: 84940663493     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-015-0635-7     Document Type: Article

References (10)

1. Vanharanta S, Massague J. Origins of metastatic traits. Cancer Cell. 2013;24:410-21.
2. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453-8.
3. Lander AD, Kimble J, Clevers H, Fuchs E, Montarras D, Buckingham M, et al. What does the concept of the stem cell niche really mean today? BMC Biol. 2012;10:19.
4. Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014;14:306-21.
5. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 2013;32:449-64.
6. Cox TR, Rumney RM, Schoof EM, Perryman L, Hoye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522:106-10.
7. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-93.
8. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271-7.
9. Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist. 2013;18:353-61.
10. Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer. 2012;48:187-95.